Eli Lilly has announced plans to establish a $3 billion (approximately Rs 26,000 crore) state-of-the-art manufacturing facility in the Netherlands, dedicated to producing its groundbreaking oral weight-loss medication Orforglipron. The facility will be set up at the Leiden Bio Science Park in Katwijk, marking a significant strategic expansion for Lilly in Europe—the second-largest market for weight-loss drugs after the United States.

The new greenfield plant will feature advanced technologies such as dock-to-dock automation, paperless manufacturing, process analytical technology, and spray-dried dispersion to enhance the effectiveness and absorption of oral medicines. According to Lilly, the site will be equipped to manufacture a variety of oral solid medicines spanning cardiometabolic, neuroscience, oncology, and immunology therapeutic areas, with Orforglipron as one of its flagship products.

David A. Ricks, CEO of Eli Lilly, expressed confidence in the project, stating, “Leiden Bio Science Park offers access to a skilled workforce, reliable infrastructure, and proven pharmaceutical manufacturing capabilities.” He further emphasized the importance of a conducive policy environment to drive innovation and quicker patient access to breakthrough medicines.

Lilly’s decision underscores its commitment to meeting the rising global demand for weight-loss therapies, especially as the company seeks FDA approval for Orforglipron following promising results from the ATTAIN clinical program, which reported average weight reductions of 12.4 kg in general patients and 10.4 kg among individuals with diabetes.

This new facility will add to Lilly’s existing network of four manufacturing plants in Europe. The company is also progressing with the development of two additional sites, one each in Ireland and Germany, cementing its position as a leader in pharmaceutical manufacturing and innovation in the region.